Chemotherapy-related fatigue (CRF) is a common and debilitating adverse effect experienced by patients with breast cancer receiving systemic antineoplastic therapy. The review reports a prevalence of approximately 30–60% of BC patients who experience fatigue during the treatment course. A proportion of patients develop long-term, persistent fatigue that negatively affects health-related quality of life and may influence broader outcomes such as functional status and prognosis. The review emphasizes the clinical importance of recognizing CRF as a frequent symptom requiring systematic assessment and management.
Patients residing in high-altitude regions encounter environmental stressors that can aggravate treatment-related symptoms. The review identifies three principal external factors prevalent at elevation: hypoxia, reduced atmospheric pressure, and variable temperature. These conditions can intensify perceived and physiologic fatigue among BC patients undergoing chemotherapy. The authors frame high-altitude exposures as additive stressors that interact with underlying CRF mechanisms rather than as sole causes of fatigue.
CRF is described as a multifactorial syndrome with overlapping biological contributors. The review highlights chronic systemic inflammation and immune system readjustment as primary mechanisms driving fatigue during and after chemotherapy. Additional pathways implicated include neuroendocrine dysregulation and mitochondrial dysfunction, which may contribute to reduced energy production, altered neurotransmission, and sustained symptomatic burden. The synthesis underscores that these mechanisms operate in concert and that inflammation and immune changes appear central in the pathogenesis described by current literature.
High-altitude hypoxia is noted to potentiate the biologic processes associated with CRF. Specifically, hypoxic exposure at elevation can enhance inflammatory signaling and influence immune regulation, thereby amplifying the pathways already implicated in chemotherapy-related fatigue. The review clarifies that hypoxia and other altitude-associated environmental factors add to the pathophysiologic milieu rather than replace the core mechanisms identified in sea-level cohorts.
The authors recommend attention to potentially reversible contributors to fatigue as part of routine assessment. Examples cited include anemia and sleep disorders, which should be identified and managed when present. While the review does not present a detailed assessment algorithm, it emphasizes that addressing reversible medical and behavioral factors is a pragmatic component of CRF care and may reduce symptom severity.
Nonpharmacological approaches receive particular emphasis as effective strategies for CRF control. The review specifically lists physical activity, cognitive behavioral therapy (CBT), and mindfulness-based interventions as having demonstrated benefit in reducing fatigue symptoms. These interventions are presented as core components of supportive care for BC patients experiencing CRF, including those living at higher altitudes, where environmental stressors may heighten symptom burden.
According to the review, evidence for pharmacological treatment of CRF remains inconclusive. The authors state that definitive pharmacologic options have not been established and that further research is required to determine effective drug-based strategies. Meanwhile, clinicians should prioritize management of reversible factors and consider nonpharmacological therapies with better-established benefits.
The review identifies a need for future investigations that explicitly consider CRF mechanisms in elevated areas and the unique environmental influences encountered there. The authors call for research designed to elucidate how hypoxia, atmospheric pressure changes, and temperature variability interact with inflammation, immune function, neuroendocrine responses, and mitochondrial biology in BC patients receiving chemotherapy. They recommend development of customized, altitude-informed treatment protocols aimed at improving quality of life for this population.
Additional article and publication details
This work is a review article published in Support Care Cancer in 2026 (volume/issue citation shown in the source). The publication lists Tao Wu, Jinming Li, Fuxing Zhao, and Zhen Liu as authors affiliated with the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital and its affiliated cancer hospital in Xining, China. PubMed identifier (PMID) 42661012 and DOI 10.1007/s00520-026-11151-6 are provided in the source record. The authors declared no competing interests and indicated ethics approval and consent to participate and for publication as not applicable.
Limitations of the source
The review summarizes mechanisms, environmental modifiers, and management approaches but does not provide granular trial-level data or specific pharmacologic recommendations. Where details such as quantitative effect sizes, study designs, or head-to-head comparisons would be needed for clinical decision-making, the source either did not report them or summarized broader conclusions. Clinicians should consult original trials and guideline documents for in-depth evidence when available.